Pharma deals way up in Q1

Investment bankers and lawyers should be writing plenty of thank-you notes to drugmakers. During the first quarter of 2009, pharma deals accounted for almost 50 percent more than all the industry's transactions announced in 2008, according to a report from The Mergermarket Group of New York and London. Quarter-over-quarter, this year's total runs more than 10 times last year's amount.

Pharma deals added up to $166 billion for the first three months of the year. You know who they are: Roche/Genentech ($47 billion), Pfizer/Wyeth ($64 billion), and Merck/Schering-Plough ($43 billion) are only the three biggest.

Mergermarket predicts that mega-deals will screech to a halt now, however, with acquisitions focusing more on companies valued at $5 billion or less. Think GlaxoSmithKline's buyout of Stiefel Labs yesterday, for instance, or any of Sanofi-Aventis' recent deals. And the group forecasts that M&A over the next few quarters will include healthy growth in stem-cell-related transactions.

- here's the release (.pdf)
- read TheStreet article

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.